RCT of IV Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Paediatric ED

PHASE1CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 3, 2025

Study Completion Date

March 3, 2025

Conditions
Migraine
Interventions
DRUG

Dexamethasone group

The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.

DRUG

Placebo group

Normal Saline 0,9% same volume

Trial Locations (1)

H3T1C4

CHU Sainte Justine, Montreal

All Listed Sponsors
lead

St. Justine's Hospital

OTHER

NCT02903680 - RCT of IV Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Paediatric ED | Biotech Hunter | Biotech Hunter